Please assess the completion status of the following clinical trial:

Trial Title: Vortioxetine to Prevent Return of Symptoms in Children With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~De novo participants~* The participant has a primary diagnosis of MDD according to DSM-5™ although co-morbid anxiety disorders will be permitted (except Post Traumatic Stress Disorder (PTSD) and Obsessive Compulsive Disorder (OCD)).~* The participant has a CDRS-R total score ≥45 at the Screening and Baseline Visits.~* The participant has a Clinical Global Impression - Severity of Illness (CGI-S) ≥4 at the Screening and Baseline Visit~Exclusion Criteria:~* The participant receives ongoing current psychotherapy that is planned to be intensified. Interpersonal psychotherapy (IPT) or cognitive behavioural therapy (CBT) are not allowed.~* The participant presents with, or has a history of, an Axis I (DSM-5TM) diagnosis of Bipolar Disorder, PTSD, OCD, Autism, Pervasive Developmental Disorder (PDD), or Schizophrenia or Schizoaffective Disorder.~* The participant has a diagnosis of attention-deficit/hyperactivity disorder (ADHD) and is not maintained on a stable dose of a methylphenidate or amphetamine for a minimum of 4 weeks prior to the study treatment.~* The participant has attempted suicide or is at significant risk of suicide~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine -open label treatment period (Type: EXPERIMENTAL): Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events.
- Vortioxetine -double-blind relapse prevention period (Type: EXPERIMENTAL): Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period
- Placebo -double-blind relapse prevention period (Type: PLACEBO_COMPARATOR): Placebo - encapsulated tablets, orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).